2021
DOI: 10.1016/j.pneurobio.2021.102031
|View full text |Cite
|
Sign up to set email alerts
|

Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer’s Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

8
54
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 62 publications
(78 citation statements)
references
References 149 publications
8
54
0
Order By: Relevance
“…The neurobiological substrate of this increased risk is likely related to a release of connectivity between VTA and DMN. Our findings are consistent with recent research that contributed to shed light on the strategic role of dopamine in AD pathophysiology [27,66,[69][70].…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…The neurobiological substrate of this increased risk is likely related to a release of connectivity between VTA and DMN. Our findings are consistent with recent research that contributed to shed light on the strategic role of dopamine in AD pathophysiology [27,66,[69][70].…”
Section: Discussionsupporting
confidence: 93%
“…Notably, the dysfunction of dopaminergic transmission has been hypothesized as a new player in the pathophysiology of AD [21][22][23][24][25][26][27][28][29][68][69][70]. Post mortem studies revealed marked loss of DA receptors in the temporal and frontal lobes of AD brains [21,23,24], regions classically involved in cognitive decline.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, c-Abl has been shown to be involved in autophagy. Chronic treatment with nilotinib, a clinically validated c-Abl inhibitor, improves autophagy, reduces Aβ levels, and prevents neurodegeneration in an Alzheimer’s mouse model ( La Barbera et al, 2021 ). In Parkinson’s, nilotinib induces cellular clearance of α-synuclein, via autophagic degradation, and protects the dopaminergic neurons, improving locomotor function in mouse models of this disease ( Hebron et al, 2013 ).…”
Section: Introductionmentioning
confidence: 99%
“…AD, as a common progressively neurodegenerative disorder, endangers the memory and cognitive abilities of people around the world [34,35]. As the universal animal model of AD, APP/PS1 mice stably display mouse/human APP located in neurons and mutant human PS1 and there are senile plaque deposits in the brain at the age of 6 months, and memory ability decline with age [36].…”
Section: Discussionmentioning
confidence: 99%